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fraction).The dose was calculated based on 3D CT-planning 
using Oncentra Master Plan and PLATO planning software. 
Dose volume constrains which were analyzed for target were: 
V100, V150, V200, D90. Patients were monitored weekly 
during radiotherapy and 1,3,6,9 and 15 months after the end 
of the treatment and then at three months interval. Follow-
up visit included physical examination, images: ultrasound of 
abdomen and chest X ray and CEA value assessment. The 
acute toxicities were graded according to the EORTC/RTOG 
scales. 
Results: Median follow up was 34,4 months (range 18-58). 
Three local recurrences were observed. One patient died of 
intercurrent disease 12 months after the implantation which 
was unrelated to the brachytherapy. Grade 1 and 2 rectal 
toxicity was reported in ten patients ( 66,7%). Four patients 
(26.6%) reported Grade 3 toxicity. One patient (6,7%) 
required hospitalization and surgical intervention. The most 
common rectal symptoms were pain, bleeding, thin stool, 
rectal urgency and frequency and acute proctitis. However 
no fatal toxicity was observed. 
Conclusions: HDR brachytherapy is a valid anal sphincter 
sparing treatment modality to carefully selected patients and 
can be successfully used for salvage in patients with no other 
treatment options. The treatment was well tolerated by 
majority of patients with acceptable degree of acute 
toxicities. Overall survival data need longer follow-up. 
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Purpose/Objective: develop a method of intraluminal 
radiotherapy for esophageal cancer. 
Materials and Methods: In RCRC 52 inoperable patients with 
esophageal cancer were treated with the use of 1 step 
method intraluminal radiotherapy esophagus. In 63.4% of 
patients - constrictive inoperable esophageal cancer, at 
36.6% - a recurrence of esophageal cancer after treatment. 
Morphologically, the tumor shows squamous cell carcinoma 
(55.8%) and adenocarcinoma of varying degrees of 
differentiation (44.2%). In 84.6% of cases of marked 
dysphagia II-IV degree. Conducting topometricheskogo 
planning endovascular office allows you to set the Intrastat 
for the intraluminal radiotherapy in residual lumen of the 
esophagus to 1mm. Irradiation is performed with high activity 
sources Ir192. Dosing at 1 cm from the active line, the length 
of the active line 5-16sm. Treatment is carried out in 3 
fractions with an interval of 6-7 days ROD = 7Gr SOD = 
35games. In 96.2% of patients treated as outpatients 
conducted. After a 2-week break in 80.8% of cases to pursue 
further therapy: 52% rate teletherapy ROD = 2g = 80iGr to 
SOD, in 28.8% of cases in combination with chemotherapy. 
Follow-up of 4-26 months. In all cases observed treatment 
effect (tumor resorption in 23.1% - the complete destruction 
of the tumor, reducing the severity of dysphagia). 
Complications: 23.1% of the cases of different severity of 
esophagitis (docked conservative), 1.9% (1 patient) - 
esophago-tracheal fistula (setting 'covering' nitinol stent). 
Results: Follow-up of 4-26 months. In all cases observed 
treatment effect (tumor resorption in 23.1% - the complete 
destruction of the tumor, reducing the severity of 
dysphagia). Complications: 23.1% of the cases of different 
severity of esophagitis (docked conservative), 1.9% (1 
patient) - esophago-tracheal fistula (setting 'covering' nitinol 
stent). 
Carrying on 1 stage esophageal intraluminal radiotherapy 
reduces the severity of dysphagia, which contributes to the 
correction of metabolic disorders and improve the overall 
condition, creates the possibility of external beam 
radiotherapy and chemotherapy in patients previously 
considered incurable, and consequently improves the results 
of treatment. 
Conclusions: Intraluminal radiotherapy of the esophagus is a 
highly effective and safe treatment for patients with 
inoperable cancer of the esophagus, especially combines with 
dysphagia tumor genesis, significantly improving the quality 
of life and its duration in these patients. 
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Purpose/Objective: The purpose of this study is to compare 
high frequency ultrasonography (HFUS) and histpathologic 
assessment done by punch biopsy to determine depth of basal 
cell carcinoma (BCC), in both superficial and nodular BCCs 
prior to brachytherapy treatment. 
Materials and Methods: This study includes 20 patients with 
10 superficial and 10 nodular BCCs. First, punch biopsy was 
done to confirm the diagnosis and to measure tumour depth 
(Breslow rate). Subsequently, HFUS was done to measure 
tumour depth to search for correlation of these two 
techniques. 
